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Abstract
Purpose: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest
clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-
at-risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has shown promise in delivering
ablative doses safely. We sought to demonstrate the benefits of SMART using a 5-fraction approach with daily on-table adaptation.
Methods and Materials: Patients with locally advanced, nonmetastatic pancreatic adenocarcinoma were treated with 50 Gy in 5
fractions (biologically effective dose10 100 Gy) with a prescribed goal of 95% planning target volume coverage by 95% of prescription,
prioritizing hard OAR constraints. Daily online adaptation was performed using magnetic resonance-guidance and on-table
reoptimization. Patient outcomes, treatment factors, and daily adaptation were evaluated.
Results: Forty-four patients were treated with SMART at our institution from 2014 to 2019. Median follow-up from date of diagnosis was
16months (range, 6.7-51.6). Late toxicity was limited to 2 (4.6%) grade 3 (gastrointestinal ulcers) and 3 (6.8%) grade 2 toxicities (duodenal
perforation, antral ulcer, and gastric bleed). Tumor abutted OARs in 35 patients (79.5%) and tumor invaded OARs in 5 patients (11.1%).
Reoptimization was performed for 93% of all fractions. Median overall survival was 15.7 months (95% confidence interval, 10.2-21.2),
while 1-year and 2-year overall survival rates were 68.2% and 37.9%, respectively. One-year local control was 84.3%.
Conclusions: This is the first reported experience using 50 Gy in 5 fractions for inoperable pancreatic cancer. SMART allows this ablative
dose with promising outcomes while minimizing toxicity. Additional prospective trials evaluating efficacy and safety are warranted.
 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Locally advanced and borderline resectable pancreatic
adenocarcinoma (LAPC) is a high mortality disease with
limited treatment options.1 Radiation therapy (RT) has
been explored as a treatment option, but recent data
indicate that conventional 3-dimensional chemoradiation
(chemoRT) may not be effective, with no overall survival
(OS) improvement of chemoradiotherapy compared with
chemotherapy alone.2 Modern radiation techniques such
as intensity modulated RT (IMRT), hypofractionation,
and stereotactic body RT (SBRT) to pancreatic tumors
may result in improved clinical outcomes.3-5 IMRT pro-
duces conformal radiation doses and subsequently
reduced toxicity rates.6 On the other hand, SBRT allows
for high conformality with delivery of ablative radiation
doses. However, the SBRT prescriptions for pancreatic
cancers have been limited to subtherapeutic prescriptions
due to nearby organs-at-risk (OAR) toxicity, with bio-
logically effective doses (BED) of less than 100 Gy (a/b
tumors Z 10).7-9 High BED radiation has been delivered,
with retrospective data indicating improved OS compared
with lower BED radiation, but this was in a highly
selected population where the tumor was at least 1 cm
away from gastrointestinal (GI) mucosal structures.4
Further, SBRT is usually contraindicated when there is
tumor invasion into the duodenum or other surrounding
GI structures.
Stereotactic magnetic resonance (MR)eguided adap-
tive radiation therapy (SMART) potentially permits
ablative doses by daily visualization and delineation of GI
structures in real-time to account for anatomic varia-
tions.10,11 Dosimetric studies and a prospective phase I
clinical trial have demonstrated that MR-guided adaptive
SBRT enables target volume dose-escalation with
simultaneous sparing of important OARs.12-15 A multi-
institutional retrospective study demonstrated that dose-
escalated SMART for patients with pancreatic cancer
may provide a survival benefit compared with more
conventional MR-guided radiation treatments.16 There are
limited published data for ablative doses of MR-guided
adaptive SBRT in pancreatic cancer. Here, we report the
first experience of patients with inoperable pancreatic
cancer treated using the SMART technique to a pre-
scription of 50 Gy in 5 fractions.
Methods and Materials
Study population
We performed an institutional review boardeapproved
retrospective analysis and compiled data on patients with
inoperable pancreatic tumors treated with SMART
therapy using the MRIdian (ViewRay Inc, Mountain
View, CA) Cobalt-60 system or MR-linear accelerator
(LINAC) system using a 5-fraction regimen. Patients with
primary localized pancreatic adenocarcinoma that was
medically inoperable, borderline resectable, or locally
advanced were included. All patients were required to
hold any systemic therapy 1 week before planned
initiation of SMART, with no plans to initiate systemic
therapy for 1 week following completion of SMART.
Pancreatic tumor resectability status was determined by
multidisciplinary tumor board consensus after review of
radiographic imaging and patient operability status.
Patients were excluded if they had metastatic pancre-
atic cancer, pancreatic tumor histologies other than
pancreatic adenocarcinoma, locally recurrent disease in
the pancreas with prior radiation therapy, a separate pre-
existing malignancy, or metastatic disease to the pancreas
from another primary site. The remaining cohort of pa-
tients received definitive 50 Gy in 5 fractions SMART for
primary pancreatic adenocarcinoma.
Simulation and initial planning
The SMART clinical workflow has been previously
described.12,17 In brief, patients initially underwent a
computed tomography (CT) and MR simulation. Free-
breathing CT simulation was acquired for dose calcula-
tion using deformable image registration and to identify
tumor dimensions. MR simulation was performed using
the adaptive MR image guided radiation therapy system,
with receiver surface coils placed on the abdomen.
The simulation MR image was selected as the primary
image for contouring OARs and treatment planning while
the CT scan was rigidly registered to the MR scan for
determining electron density. The gross tumor volume
(GTV) was identified using data from both the CT and
MR simulation scans, and the planning target volume
(PTV) was defined as a 5 mm volumetric expansion from
the GTV. The prescribed dose for all plans was 50 Gy in 5
fractions with the goal of 95% PTV coverage with 95% of
prescription dose (47.5 Gy), subject to hard OAR con-
straints. The constraint for OARs, including esophagus,
stomach, duodenum, small bowel, and large bowel was
volume receiving 36 Gy or greater (V36 Gy) < 0.75 cm3
(<0.5 cm3 for MR LINAC) with a spinal cord max of
V25 Gy < 0.5 cm3. The liver constraint was 700 cm3 <
20 Gy, V25 Gy < 33%, and mean <20 Gy. If PTV
coverage could not be met due to violation of hard OAR
constraints, then PTV coverage was sacrificed in accor-
dance with a strict isotoxic approach.
Daily online adaptive planning and treatment
Our online plan adaptation and plan quality assurance
processes have been previously published.17,18 Briefly,
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before delivery of each fraction, a volumetric MR imag-
ing was performed for setup and localization. The initial/
prior treatment plan was loaded onto the daily MR image
using deformable image registration, and new OAR
contours were generated based on daily patient anatomy.
Assessment of the initial/prior treatment plan on the new
MR image anatomy was performed and a new plan
generated if an OAR constraint was violated or if there
was the potential to improve PTV coverage. If the new
plan generated still violated OAR constraints, then the
plan was normalized down to meet constraints. Adaptive
plans were evaluated and compared with the prior plan by
dose-volume histogram, dosimetric constraints, and
isodose distribution at the treatment console. In instances
where dose constraints were not exceeded with the orig-
inal (or prior fraction) plan, adaptation was only used if
significant improvement of PTV coverage would be ob-
tained with the new plan. In these scenarios, if all OAR
constraints were met, adaptation was performed to
normalize the plan dose up to the OAR that was closest to
the constraint to maximize coverage.
All fractions were delivered with real-time MR guid-
ance including cine MR gating on the GTV as previously
described.18 A gating window region of interest was
determined by the treating radiation oncologist and eval-
uated for each treatment.
Workflow of dosimetric analysis during online
adaptation
Dosimetric comparison of the initial and online reop-
timized plans was performed during online adaptation.
Initial plans were defined as the SBRT plan generated at
the time of initial treatment planning that hypothetically
delivered all treatment fractions without adaptation.
Reoptimized plans were defined as the SMART plans
after reoptimization with online adaptation. GTV and
PTV coverage were compared between initial and reop-
timized plans by comparing dose to 50% of target volume
(D50%), dose to 95% of target volume (D95%), and dose
to 98% of target volume (D98%). PTV coverage was
further compared using the volume receiving 100% of
prescription dose (V100%) and by determining the
number of fractions achieving the goal of 95% PTV
coverage by 47.5 Gy (95% of prescription dose). OAR
dosimetric analysis included quantifying the extent and
frequency of violation of max dose constraints of OARs
between both initial and reoptimized plans.
Clinical endpoints and statistics
Patient, tumor, and treatment factors were investigated
and compiled into a prospectively maintained, de-
identified database. Toxicity was assessed using the Na-
tional Cancer Institute Common Terminology Criteria for
Adverse Events (version 5.0). Acute toxicity was defined
as less than or equal to 3 months after SMART and late
toxicity was defined as more than 3 months after SMART.
Follow-up time was calculated from the completion
fraction of SMART. Progression free survival (PFS) was
calculated from date of diagnosis until first progression
event, death, or censoring at the date of last clinical
follow-up. In addition, local control, OS, and distant
failure free survival (DFFS) were evaluated. OS was
determined from date of diagnosis until death or date of
last follow-up. DFFS was determined as the time from
date of diagnosis until first distant metastasis, death, or
date of last follow-up. Treatment-free interval was also
calculated from completion of SMART until initiation of
systemic therapy for progression or date of last follow-up.
Treatment-free interval was only calculated for patients
who were initially observed without treatment after
SMART but required systemic therapy due to future
progressive disease or for patients who were initially
observed without treatment after SMART and were alive
at last follow-up.
The product-limit method of the Kaplan-Meier method
was used to estimate these endpoints. All statistical tests
were 2-sided. A P value less than .05 was considered
statistically significant. All analyses were completed
using SPSS software, version 22.
Results
Patient and treatment characteristics
From January 2015 through January 2019, we identi-
fied 85 patients with pancreatic tumors treated with
SMART therapy using a 5-fraction regimen. Of these, 44
patients met inclusion criteria as noted in Figure 1. There
were 29 men (65.9%) with a median age of 71 for the
entire cohort (range, 42-93 years). Median follow-up time
from date of diagnosis was 16 months (range, 6.7-51.6
months). Eastern Cooperative Group (ECOG) perfor-
mance status was 0 in 13 patients (29%), ECOG 1 in 20
patients (46%), ECOG 2 in 9 patients (21%), and ECOG 3
in 2 patients (5%). Among all tumors, 35 (79.5%) were
located in the pancreatic head, and 9 were located in the
body or tail. Four patients (9.1%) had regional node
positive disease at initial diagnosis. Additional baseline
characteristics are listed in Table 1. When assessing the
proximity of the pancreatic tumor to surrounding OARs,
tumor was noted to abut OARs in 35 patients (79.5%),
and tumor was invading OARs in 6 patients (13.6%).
Among these 6 patients with tumor invading OARs, 4
patients had duodenal/jejunal invasion, 1 patient had
gastric invasion, and 1 patient had adrenal invasion.
Serum cancer antigen 19-9 levels were available for 29
patients (65.9%) at initial diagnosis, with a median level
of 293.3 U/mL (range, 2-3362 U/mL). At the time of
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initial diagnosis, 28 patients (63.6%) were considered
unresectable, 6 patients (13.6%) were borderline resect-
able, and 10 patients (22.7%) were medically inoperable.
Thirty-six patients (82%) received neoadjuvant
chemotherapy before SMART. The most common initial
neoadjuvant chemotherapy regimen administered was
FOLFIRINOX, which was administered to 36% of all
patients. Nab-paclitaxel and gemcitabine were adminis-
tered to 34% of all patients, and 11% received gemcita-
bine alone or nab-paclitaxel alone. The median duration
of time from the start of neoadjuvant chemotherapy until
the initiation of SMART was 5.8 months (range, 1-27.8
months). Adjuvant post-SMART chemotherapy was
administered to 19 patients (43.2%), with the most com-
mon regimen being FOLFIRINOX or FOLFOX.
SMART baseline plans and indications
Thirty-eight patients were treated on the Cobalt-60
system, and 6 patients were treated with the MR-LINAC
system. Median GTV and PTV at baseline were 52 cm3
(range, 7-236 cm3) and 109 cm3 (range, 25-419 cm3).
Based on the original plan, the median value for the mean
PTV dose was 48 Gy (range, 38-60 Gy), and the median
value for max PTV dose was 67 Gy (range, 58-78 Gy).
SMART therapy was delivered for various indications.
Twenty-four patients (54.5%) received SMART after
interval imaging demonstrated persistent unresectable
disease despite neoadjuvant chemotherapy. Eight patients
(18.2%) received SMART after they could no longer
tolerate chemotherapy due to toxicity. Eight patients
(18.2%) received SMART after never receiving chemo-
therapy due to patient refusal of chemotherapy or the
discretion of the oncology team to forgo chemotherapy in
lieu of SMART. Four patients (9%) received SMART
after evidence of progressive disease while on neo-
adjuvant chemotherapy.
Plan adaptation
Out of the 220 total delivered fractions (93%), 204
fractions of SMART were adapted and chosen in lieu of
the prior baseline plan. On-table dosimetry revealed 181
out of 220 fractions (82.3%) of the unoptimized plans
initially violated OAR constraints. The most commonly
violated individual OAR constraints on the initial unop-
timized plans were the duodenum (67.7% of fractions)
and small bowel (38.1% of fractions). Frequently, multi-
ple OARs were found to violate dose constraints simul-
taneously on the unoptimized plans (49.1% of fractions).
Figure 2 provides an example of on-table adaptation
comparing the original plan with the plan after on-table
adaptation.
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram.
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Surgery and treatment response
After multidisciplinary review, 4 patients (9.1%) were
deemed resectable after completion of SMART. One pa-
tient’s surgery was aborted intraoperatively due to
extensive fibrosis secondary to SMART. Among the 3
remaining patients undergoing pancreaticoduodenectomy,
1 patient achieved a pathologic complete response (pCR)
with a negative margin resection, 1 patient had a near-
pCR with 5% residual viable tumor with a negative
margin resection, and 1 patient had residual disease with a
positive margin resection and lymph node positivity. No
patients received postoperative systemic therapy. Of all
patients deemed resectable after SMART, 3 patients were
alive at 17.6 months, 21.5 months, and 28.2 months since
diagnosis. One patient died of a pulmonary embolism at
8.8 months since diagnosis. Among the 4 patients
undergoing post-SMART surgery, postoperative compli-
cations included 1 patient developing portal vein anasto-
mosis leakage and thrombosis with resultant ascites
requiring several weeks of total parenteral nutrition and
oral diuretics; otherwise, no complications were noted in
the remaining patients.
Patient outcomes
Median OS was 15.7 months (95% confidence interval
[CI], 10.2-21.2 months), while 1-year and 2-year OS rates
were 68.2% and 37.9%, respectively. Median PFS was
12.4 months (95% CI, 10.7-14.1 months), while 1-year
and 2-year PFS rates were 52.3% and 13.9%, respec-
tively. Local control at 1 year and 2 year was 84.3% and
59.3%, while the overall local control rate at last follow-
up was 50.8%. Median DFFS was 21.3 months (95% CI,
17.5-25.1 months), and 1-year and 2-year DFFS were
78% and 37.8%, respectively. Kaplan Meier curves are
displayed in Figure 3.
At last follow-up, 10 patients (22.7%) were alive with
no evidence of disease recurrence locally or systemically.
Of the 10 patients who did not receive chemotherapy
immediately following SMART, the median
chemotherapy-free interval after SMART completion was
7.1 months (range, 2.3-19.8 months), with 5 patients
experiencing a treatment break of greater than 12 months.
Toxicity
Acute toxicity was defined as that within 3 months of
SMART, and the most common side effects included
grade 1 or 2 fatigue, nausea, abdominal pain, and anorexia
with no grade 3 toxicities. Late toxicity was defined as
that more than 3 months after SMART, and there were 3
grade 2 toxicities (6.8%) and 2 grade 3 toxicities (4.6%)
after SMART. Among grade 2 toxicities, 1 patient
developed a duodenal perforation, and 2 patients devel-
oped gastric/pyloric ulcers, with all 3 toxicities managed
medically. Two patients developed grade 3 gastric or
duodenal ulcers requiring invasive intervention, but none
were life-threatening. No grade 4 or 5 events occurred.
Among those patients with evidence of GI invasion, no
grade 3þ toxicities were observed.
Discussion
SBRT using MRI guidance for LAPC in 5 fractions
allows for the consolidation of RT into a convenient, short
therapeutic course without the significant machine utility
required for conventional fractionation. To our knowl-
edge, this is the first reported experience of delivering 50
Gy in 5 daily fractions to treat inoperable pancreatic
adenocarcinoma. Prior experience has demonstrated the
feasibility of high BED ablative doses for pancreas
Table 1 Patient demographics and baseline characteristics
All patients (n Z 44)
Follow-up (median and range) 16 mo (7-52)
Age, year










Location of tumor, no. (%)
Head 35 (80)
Body/tail 9 (20)
Proximity to OARs, no. (%)
Abutting OAR 35 (80)
Invading OAR 5 (11)
No tumor involvement 4 (9)
Resectability at diagnosis, no. (%)
Unresectable 28 (64)
Borderline resectable 6 (14)
Medically inoperable 10 (23)
Neoadjuvant chemotherapy, no. (%)
FOLFIRINOX 16 (36)
Nab-paclitaxel and gemcitabine 15 (34)
Gemcitabine alone 3 (7)
Nab-paclitaxel alone 2 (4)
No neoadjuvant 8 (18)
Radiation modality, no. (%)
Cobalt-60 system 38 (86)
MR-LINAC system 6 (14)
Abbreviations: ECOG Z Eastern Cooperative Oncology Group;
MR-LINAC Z magnetic resonance-guided linear accelerator;
OAR Z organs-at-risk.
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tumors in greater than 5 fractions, but this has been highly
selective for patients without tumors abutting nearby
OARs; however, this cohort included all tumor geogra-
phies. Given the proximity of GI OARs to the pancreas, a
significant number of patients with LAPC are not SBRT
candidates. In this study of ablative 5 fraction SMART,
80% of patients had tumor abutting an OAR, and yet the
grade 3 toxicity was comparable to previous experience
of nonablative prescriptions7 or highly selected patients.4
Importantly, although GI endoluminal structure invasion
by tumor is traditionally a contraindication to SBRT, 5
such patients were treated with this high ablative dose,
with no patients demonstrating grade 3 or greater late
toxicity. We attribute this largely to the daily adaptation
and gating allowed by MR guidance along with adherence
to strict OAR constraints, occasionally at the expense of
PTV coverage.16-18 The frequency with which plan
adaptation was required further establishes that daily
organ position variation can result in a dose distribution to
structures that was not anticipated with initial planning.
Duty cycles (beam on time) for gated pancreas treatments
at our institution usually range from 50% to 80%, indi-
cating that without proper motion management, up to
50% of conventionally delivered radiation (free-breath-
ing) can potentially miss tumor or overdose OARs.
The LAP 07 trial is the most recently reported phase 3
study conducted in a similar population of patients with
LAPC, randomized to chemotherapy or chemoRT in
those with stable disease after induction chemotherapy.
This study found no benefit to chemoRT over chemo-
therapy in regard to PFS or OS.2 However, the RT
delivered in this trial used large margins (3 cm superior/
inferior and 1.5 cm axial) for target volumes, and used the
3-dimensional conformal technique instead of IMRT and
delivered nonablative doses.3 Despite these limitations, a
benefit in local control was seen with chemoRT.2
Furthermore, advances in induction chemotherapy,
including FOLFIRINOX and nab-paclitaxel/gemcitabine
regimens, have translated into improved OS and may
provide additional benefit over the gemcitabine alone
regimen of LAP 07.19,20 Although the OS reported here is
similar to those in conventional chemoradiation series
such as LAP 07 and CT-based SBRT studies, the
advantage of SMART is that it appears to allow safe
treatment of tumors that abut or invade nearby OARs.
Furthermore, SMART provides ablative doses of radia-
tion in 5 treatments (50 Gy in 5 fractions, BED10 100 Gy),
compared with 67.5 Gy in 15 fractions (BED 97.9)4,21,22
or 54 Gy in 30 fractions (BED 63.7),2 allowing more
rapid transition to multiagent chemotherapy if indicated.
Previous work on SMART and abdominal tumors
demonstrated dosimetric advantages such as PTV dose
escalation and OAR sparing. Our study demonstrates the
feasibility of using a similar SMART approach for
pancreatic tumors.12,18,23 We demonstrated low rates of
grade 2 and 3 toxicity with no grade 4 or 5 events, despite
a majority of tumors abutting at least 1 OAR. Importantly,
many patients required no further chemotherapy for many
months after SMART, with a median treatment-free in-
terval of 7 months, and several patients experienced a
treatment break of 12 months or more. These low rates of
toxicity and chemotherapy-free intervals are important to
consider in this cohort of patients with unresectable dis-
ease that may be too frail to tolerate long courses of full
dose chemotherapy.
It is important to note that our reported OS and PFS
rates compare favorably to outcomes from other studies
looking at LAPC SBRT, with our median OS of 15.7
months versus 13.9 months in the Herman et al7 study and
5.7 months for Hoyer et al,8 despite our cohort including
Figure 2 Example of stereotactic magnetic resonance-guided adaptive radiation therapy (SMART), on-table adaptation. Seventy-six-
year-old patient with lesion at pancreatic head invading duodenum who underwent adaptation for all 5 fractions. (A) Axial and sagittal
original, predicted treatment plan for patient. (B) Treatment plan for the delivered fraction after adaptation. (C) The corresponding dose-
volume histogram (DVH) with the solid representing the predicted, original plan and the dashed representing the delivered, adapted
plan.
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older patients with worse performance status.2 These
survival numbers are important to consider in the context
of LAP 07, which had a median OS of 15.2 months in the
chemoRT arm with a median age of 62 and 7% of patients
with an ECOG score of 2 and no ECOG 3 patients,
whereas our SMART cohort had a median age of 71 with
21% of patients with a ECOG performance status of 2 and
5% with a status of ECOG 3. However, our OS was
inferior to that in the Kharofa et al24 study, which reported
a median OS of 21 months, which can be explained by
our inclusion of higher risk, treatment refractory patients.
Unlike Kharofa et al we did not use any elective nodal
coverage; however, local control was high likely due to
the greater ablative doses used in our experience.24 In our
cohort, the application of SMART led to a 1-year local
control rate of 84.3%, with the majority of patients dying
of metastatic disease. This compares favorably to the 78%
1-year local control of the Herman et al7 study, with our
cohort experiencing much lower grade 3 late toxicity
(4.5% compared with 12.7%).
Although all patients were considered to have LAPC at
initial diagnosis, 4 patients were deemed resectable after
SMART with 1 pCR and 1 near-pCR, with 3 alive at last
follow-up. Patients who underwent resection had few
postoperative complications, with 1 patient unable to
undergo resection due to extensive post-RT fibrosis. This
limited experience suggests a possible role for SMART to
down-stage locally advanced pancreatic tumors for
resection. Institutionally, we have begun to perform sur-
gery earlier after SMART with reduced signs of fibrosis,
relative safety, and the potential to prolong survival for
this subgroup of patients.
Further studies are needed to determine whether SBRT
delivered earlier in the treatment course can decrease
metastatic spread. These studies are inherently difficult, as
induction chemotherapy also serves as a trial period
during which subclinical metastatic disease present at
diagnosis can manifest. Thus, a single arm SBRT upfront
study will also include many patients with subclinical
metastatic disease, with the results erroneously indicating
that SBRT results in high distant failure. A randomized
trial between SBRT versus induction chemotherapy first
may potentially evaluate the effect of local radiation on
distant failure while allowing for equal accrual of sub-
clinical metastatic patients in each arm. Until such data
are available, it is important to consider that local control
is a significant metric in LAPC, as up to 30% of patients
will ultimately die of locally progressive disease.25 Given
the high local control rate, SMART to the pancreatic
primary should be considered as a low risk local therapy
with the potential to increase OS and decrease metastatic
spread of disease.
Limitations of our study include its small sample size
and retrospective nature. Some may criticize that there
was patient selection bias for the manuscript or treatment.
However, as noted, 93% of our patient population
received this ablative radiation dose with tumor abutting
or invading OARs. This is in stark contrast to previous
experience that excluded tumors within 1 cm of OARs out
of concern for toxicity with such high radiation doses.4
The local control is numerically comparable or slightly
better than historical CT-based SBRT trials.7 Recent
data24 indicate the potential need to cover elective high-
risk nodal regions, a practice that has historically been
avoided owing to difficulty in meeting dose constraints.
SMART may permit coverage of these enlarged target
volumes, resulting in higher local control rates while
minimizing toxicity. Lastly, the majority of our patients
were treated on the Cobalt-60 system, and better OAR
sparing may be possible if patients are treated on the MR-
LINAC system with a steeper dose gradient.
Conclusions
Overall, these data demonstrate the safety and treat-
ment efficacy of MR-guided adaptive SBRT in LAPC. As
patients with medically inoperable or unresectable
pancreatic cancer have few treatment options, a 5-fraction
SMART approach offers a treatment modality with
Figure 3 Kaplan-Meier estimates of survival for (A) progression-free survival and (B) overall survival. The 95% confidence intervals
are included as dotted lines.
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convenience, limited toxicity, and significant local control
benefit.
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